MedTrace Logo

Real-world Treatment Patterns and Clinical Outcomes in EGFR-mutant Unresectable Locally Advanced NSCLC

NCT04304638 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 450

Last updated 2020-03-11

No results posted yet for this study

Summary

The investigators will obtain a cohort of patients from multiple large cancer centers in China and try to unravel the efficacy of "radiotherapy combined with EGFR-TKI", which may provide some evidences for the treatment of stage III-inoperable NSCLC.

Conditions

  • Non Small Cell Lung Cancer
  • Stage III Non-small-cell Lung Cancer
  • EGFR Mutation-Related Tumors

Interventions

RADIATION

radiation or chemo-radiation

standard treatment for stage III lung cancer

DRUG

EGFR-TKI Inhibitor

the standard treatment for stage IV lung cancer with EGFR mutation

Sponsors & Collaborators

  • Chinese Academy of Medical Sciences

    lead OTHER

Principal Investigators

  • Luhua Wang, MD · Cancer center of Chinese Academy of Medical Sciences

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-31
Primary Completion
2020-05-31
Completion
2020-06-30
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04304638 on ClinicalTrials.gov